.

Make Better Decisions

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Novartis
Federal Trade Commission
Chinese Patent Office
Colorcon
Cipla
Boehringer Ingelheim
Fuji
AstraZeneca
Teva
Chubb

Generated: January 19, 2018

DrugPatentWatch Database Preview

Patents Expiring in January 2031

« Back to Dashboard

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Eagle PharmsBENDEKAbendamustine hydrochlorideSOLUTION;IV (INFUSION)208194-001Dec 7, 2015RXYesYes➤ Subscribe➤ SubscribeY
Eagle PharmsBENDEKAbendamustine hydrochlorideSOLUTION;IV (INFUSION)208194-001Dec 7, 2015RXYesYes➤ Subscribe➤ Subscribe
Eagle PharmsBENDEKAbendamustine hydrochlorideSOLUTION;IV (INFUSION)208194-001Dec 7, 2015RXYesYes➤ Subscribe➤ SubscribeY
Janssen PharmsINVEGA SUSTENNApaliperidone palmitateSUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR022264-005Jul 31, 2009RXYesNo➤ Subscribe➤ SubscribeTREATMENT OF SCHIZOPHRENIA
Janssen PharmsINVEGA SUSTENNApaliperidone palmitateSUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR022264-005Jul 31, 2009RXYesNo➤ Subscribe➤ Subscribe
Janssen PharmsINVEGA SUSTENNApaliperidone palmitateSUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR022264-004Jul 31, 2009RXYesYes➤ Subscribe➤ Subscribe
Janssen PharmsINVEGA SUSTENNApaliperidone palmitateSUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR022264-004Jul 31, 2009RXYesYes➤ Subscribe➤ SubscribeTREATMENT OF SCHIZOPHRENIA
Janssen PharmsINVEGA SUSTENNApaliperidone palmitateSUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR022264-003Jul 31, 2009RXYesNo➤ Subscribe➤ Subscribe
Janssen PharmsINVEGA SUSTENNApaliperidone palmitateSUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR022264-003Jul 31, 2009RXYesNo➤ Subscribe➤ SubscribeTREATMENT OF SCHIZOPHRENIA
Janssen PharmsINVEGA SUSTENNApaliperidone palmitateSUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR022264-002Jul 31, 2009RXYesNo➤ Subscribe➤ SubscribeTREATMENT OF SCHIZOPHRENIA
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
McKesson
Colorcon
Queensland Health
Federal Trade Commission
Daiichi Sankyo
Fish and Richardson
Covington
Merck
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2018 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot